Correzione dell' autore: Casdatifan mostra una risposta duratura legata alla biologia HIF-2α nel cancro renale

A correction has been issued regarding an article published in Nature on 1 July 2026, titled “Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.” The error concerns the spelling of one of the authors, Jaime Merchán, who was initially listed as Jamie Merchan. The corrected names appear in both the HTML and PDF versions of the article. The study, led by Toni K. Choueiri and colleagues, explores the therapeutic potential of Casdatifan, a drug targeting the hypoxia-inducible factor 2 alpha (HIF-2α) pathway, in patients with advanced kidney cancer. The research builds upon earlier findings that suggested HIF-2α plays a key role in tumor progression and resistance to certain therapies. By inhibiting this pathway, Casdatifan appears to induce a sustained clinical response in some patients, offering new hope for treatment options in this challenging disease. The study was conducted by a multidisciplinary team of researchers affiliated with leading cancer centers across the United States and South Korea. Key contributors include Jaime Merchán from the University of Miami Sylvester Comprehensive Cancer Center, Amita Patnaik from the START Center for Cancer Research, and Brian I. Rini from the Vanderbilt-Ingram Cancer Center. Additional collaborators come from institutions such as the Dana-Farber Cancer Institute, the Cleveland Clinic, and the Karmanos Cancer Center, highlighting the collaborative nature of the research effort. The trial involved patients diagnosed with metastatic renal cell carcinoma, a type of kidney cancer known for its aggressive behavior and limited treatment options. Participants received Casdatifan as part of a phase II clinical trial, and their responses were monitored over time. The results showed that a subset of patients experienced prolonged remission, suggesting that the drug's mechanism of action, targeting HIF-2α, may offer a more effective approach than previously available treatments. The findings have sparked interest among oncologists and researchers working in the field of targeted therapy for kidney cancer. The study provides further evidence supporting the hypothesis that HIF-2α inhibition could be a viable strategy for managing resistant tumors. However, the exact mechanisms underlying the durable response remain under investigation, and additional studies will be needed to confirm these preliminary results. The research team includes several prominent figures in oncology, including Paul Foster and Rana R. McKay from Arcus Biosciences, Inc., the company behind the development of Casdatifan. Their involvement underscores the growing importance of pharmaceutical companies in advancing precision medicine approaches for complex cancers. The collaboration between academic institutions and industry partners reflects a broader trend toward translational research aimed at improving patient outcomes through innovative drug development. The publication of the correction highlights the rigorous standards maintained by scientific journals to ensure accuracy and transparency. While the initial error was minor, it serves as a reminder of the importance of careful peer review and editorial oversight in maintaining the integrity of scientific communication. The revised article now accurately represents the contributions of all co-authors, ensuring proper recognition of their work.